ResMed upgraded to Outperform as price target raised
RBC Capital upgraded ResMed to Outperform from Sector Perform and lifted its price target to $262 from $244.
ResMed rose Tuesday after receiving an upgrade and higher price target on Wall Street. RBC Capital raised the stock to Outperform from Sector Perform and increased its price target to $262 from $244, citing growing dem…